41
Participants
Start Date
May 31, 2011
Primary Completion Date
December 31, 2012
Study Completion Date
March 31, 2013
Methylphenidate, non-retard
Medication (methylphenidate, non-retard) will be titrated to optimal response within 6 weeks, with a maximum of 10 mg/day in week 1, 20 mg/day in week 2, 30 mg/day in week 3, 40 mg/day in week 4, 50 mg/day in week 5, and 60 mg/day in week 6, unless adverse effects emerged. After successful adjustment, medication will be maintained until week 6. Dosing will be based on at least two-weekly evaluations by a psychiatrist, including an interview with a review of symptoms and side effects, completion of the Clinical Global Impression (CGI) scale and completion of a standardised Side Effects Rating Scale for psychostimulants (SERS). The maximal daily dosage of MPH is 60 mg. Within this double blind study the same procedure is applied for the placebo condition.
Placebo
Clinic for Psychiatrie, Psychosomatics and Psychotherapy, Würzburg
Collaborators (1)
German Research Foundation
OTHER
Wuerzburg University Hospital
OTHER